Table 2b:
RBD IgG antibody levels after two and three vaccinations in KTR categorized by immunosuppressive regimen with or without mycophenolate mofetil.
| 2 vaccinations | 3 vaccinations | |||||||
|---|---|---|---|---|---|---|---|---|
| MMF | MMF | |||||||
| All | No | Yes | P a | All | No | Yes | P a | |
| KTR, n (%) | 1583 (100) | 554 (35) | 1029 (65) | 964 (100) | 355 (37) | 609 (63) | ||
| RBD IgG Ab level (BAU/mL) | 66 (8–573) | 340 (50–1492) | 20 (3–113) | <.001 | 259 (26–1008) | 437 (74–1445) | 165 (16–791) | <.001 |
| RBD IgG seroconversion rate, n (%) | 780 (49) | 412 (75) | 365 (35) | <.001 | 675 (70) | 277 (78) | 398 (65) | <.001 |
| RBD IgG antibody level >1000 BAU/mL, n (%) | 263 (17) | 182 (33) | 81 (8) | <.001 | 244 (25) | 117 (33) | 127 (21) | <.001 |
Note: Antibody levels, seroconversion rates, and rates of high-level antibody response (>1000 BAU/ml) after two and three SARS-CoV-2 vaccinations for all KTR, and according to an immunosuppressive regimen with or without mycophenolate mofetil (MMF).
Ab: antibody.
aDifference between ‘MMF yes’ and ‘MMF no’.